Immunotherapy has made tremendous progress as cancer-directed therapy has evolved, particularly in the field of T cell-engaging therapies. Common and serious side effects of these types of therapies include Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Join us as Bejal Kikani, MSN, FNP-BC, WHNP-BC, discusses the recognition, grading, and treatment of these toxicities.